The estimated Net Worth of Pharma, Inc. Theracour is at least $55.6 million dollars as of 15 October 2009. Pharma Theracour owns over 20,000 units of NanoViricides Inc stock worth over $55,539,805 and over the last 15 years Pharma sold NNVC stock worth over $105,750.
Sign up
Pharma Theracour NNVC stock SEC Form 4 insiders trading
Pharma has made over 5 trades of the NanoViricides Inc stock since 2009, according to the Form 4 filled with the SEC. Most recently Pharma sold 20,000 units of NNVC stock worth $15,000 on 15 October 2009.
The largest trade Pharma's ever made was selling 61,000 units of NanoViricides Inc stock on 30 July 2009 worth over $45,140. On average, Pharma trades about 28,500 units every 16 days since 2009. As of 15 October 2009 Pharma still owns at least 34,073,500 units of NanoViricides Inc stock.
You can see the complete history of Pharma Theracour stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Pharma Theracour's mailing address?
Pharma's mailing address filed with the SEC is 135 WOOD STREET, SUITE 205, WEST HAVEN, CT, 06516.
Insiders trading at NanoViricides Inc
Over the last 15 years, insiders at NanoViricides Inc have traded over $1,608,110 worth of NanoViricides Inc stock and bought 1,581,444 units worth $2,879,162 . The most active insiders traders include Milton Boniuk, Anil Diwan et Pharma, Inc. Theracour. On average, NanoViricides Inc executives and independent directors trade stock every 77 days with the average trade being worth of $126,113. The most recent stock trade was executed by Milton Boniuk on 11 November 2015, trading 25,000 units of NNVC stock currently worth $30,000.
What does NanoViricides Inc do?
nanoviricides, inc., a nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. its products pipeline includes herpecide dermal topical and eye drops for the treatment of shingles, phn, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and herpecide intraocular injection for viral acute retinal necrosis. the company also develops flucide broad-spectrum anti-influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; nanoviricide eye drops for viral diseases of the external eye; denguecide for treatment of all types of dengue viruses; and hivcide that is an escape-resistant anti-hiv nanoviricide. in addition, it is also involved in research and development of other nanoviricides drug projects for treatment of different viruses and indications; and herpecide program expansion drug projects for different herpes viruses for different indications. nanovir
What does NanoViricides Inc's logo look like?
Complete history of Pharma Theracour stock trades at NanoViricides Inc
NanoViricides Inc executives and stock owners
NanoViricides Inc executives and other stock owners filed with the SEC include:
-
Anil Diwan,
Executive Chairman of the Board, President -
Dr. Anil R. Diwan Ph.D.,
Exec. Chairman, Pres, CEO & Sec. -
Meeta Vyas,
Chief Financial Officer -
Meeta R. Vyas B.S., M.B.A., SB, MBA,
Chief Financial Officer -
Brian Zucker,
Independent Director -
Theodore Rokita,
Independent Director -
Makarand Jawadekar,
Independent Director -
Stanley Glick,
Independent Director -
Dr. Randall W. Barton Ph.D.,
Chief Scientific Officer & Chief Regulatory Officer -
Milton Boniuk,
-
Eugene Seymour,
-
Pharma, Inc. Theracour,
10% owner